plasminogen, human

Ryplazim (plasminogen, human-tvmh) is a plasma-derived human plasminogen replacement therapy indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). This rare genetic disorder is caused by mutations in the *PLG* gene, leading to deficient plasminogen activity and the subsequent accumulation of extravascular fibrinous deposits on mucous membranes. These deposits result in ligneous lesions that can impair organ function, most notably causing ligneous conjunctivitis which can lead to blindness. Ryplazim functions by replenishing endogenous plasminogen levels; once administered, it is converted into the active enzyme plasmin by tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA), which then degrades fibrin and resolves existing lesions while preventing new ones. The drug was originally developed by ProMetic BioTherapeutics and was the first FDA-approved treatment for this condition.

Brand names

Ryplazim

Other names

plasminogen, human-tvmhhuman Glu-plasminogenPlasminogen (Human)